PT  - JOURNAL ARTICLE
AU  - ALEXIS LEONARD
AU  - JOHANNES E. WOLFF
TI  - Etoposide Improves Survival in High-grade Glioma: A Meta-Analysis
DP  - 2013 Aug 01
TA  - Anticancer Research
PG  - 3307--3315
VI  - 33
IP  - 8
4099  - http://ar.iiarjournals.org/content/33/8/3307.short
4100  - http://ar.iiarjournals.org/content/33/8/3307.full
SO  - Anticancer Res2013 Aug 01; 33
AB  - Background: The purpose of this meta-analysis was to evaluate the therapeutic efficacy of topoisomerase inhibitors in the treatment of high-grade gliomas (HGGs). Materials and Methods: Using median overall survival (mOS) and survival gain, we compared the efficacy of chemotherapy drugs in a meta-analysis of 624 HGG studies, including 44,850 patients from studies published between 1976 and 2011. Results: Patient cohorts treated with etoposide had significant improvement in mOS (15.66 months vs. 13.27 months, p=0.026, 49 vs. 795 cohorts) and significant survival gain advantage (p=0.022) over cohorts treated without etoposide. In contrast, patient cohorts treated with irinotecan had significantly worse mOS (10.20 vs. 13.55 months, p=0.008, 35 vs. 810 cohorts) and a disadvantage compared to cohorts treated without irinotecan in survival gain analysis. Conclusion: Results from this analysis suggest that etoposide may improve overall survival for patients with HGG, whereas the use of irinotecan might result in inferior outcomes.